Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oncorus Inc (ONCR)

Oncorus Inc (ONCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 3,288
  • Shares Outstanding, K 26,095
  • Annual Sales, $ 0 K
  • Annual Income, $ -77,420 K
  • EBIT $ -88 M
  • EBITDA $ -85 M
  • 60-Month Beta 1.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.11
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.49
  • Most Recent Earnings $-1.18 on 05/22/23
  • Next Earnings Date 03/22/24
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0100 +1,160.00%
on 12/08/23
0.2000 -37.00%
on 12/29/23
+0.1050 (+500.00%)
since 11/29/23
3-Month
0.0100 +1,160.00%
on 12/08/23
0.2000 -37.00%
on 12/29/23
+0.0976 (+343.66%)
since 09/29/23
52-Week
0.0100 +1,160.00%
on 12/08/23
0.4700 -73.19%
on 02/03/23
-0.1292 (-50.63%)
since 12/29/22

Most Recent Stories

More News
Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates

Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022Company remains on track...

ONCR : 0.1260 (-3.08%)
Oncorus Appoints Douglas Fambrough to Board of Directors

-Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 ...

ONCR : 0.1260 (-3.08%)
Oncorus to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...

ONCR : 0.1260 (-3.08%)
Oncorus to Present at the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...

ONCR : 0.1260 (-3.08%)
Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates

Additional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022Preclinical...

ONCR : 0.1260 (-3.08%)
Oncorus Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting

– ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration – – vRNA Immunotherapy Platform has the potential...

ONCR : 0.1260 (-3.08%)
Chameleon Biosciences Appoints Silicon Valley Scientist and Entrepreneur, Dr. Thomas Chalberg, to Board Position

BERKELEY, CA / ACCESSWIRE / January 5, 2022 / Chameleon Biosciences Inc., a company developing the EVADERTM platform to produce next-generation gene therapies that are more potent and less immunogenic,...

ONCR : 0.1260 (-3.08%)
DPS Group Tapped by Oncorus to Design GMP Clinical Manufacturing Facility

Clinical stage biopharmaceutical company focused on viral immunotherapies building out state-of-the-art, 88,000 square foot facility in Massachusetts BOSTON, MA / ACCESSWIRE / September 22, 2021 / DPS...

ONCR : 0.1260 (-3.08%)

Business Summary

Oncorus Inc. is a clinical stage biopharmaceutical company. It is focused on developing viral immunotherapies to transform outcomes for cancer patients. The company's product candidate includes ONCR-177, which is in clinical stage. Oncorus Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 0.2507
2nd Resistance Point 0.2253
1st Resistance Point 0.1757
Last Price 0.1260
1st Support Level 0.1007
2nd Support Level 0.0753
3rd Support Level 0.0257

See More

52-Week High 0.4700
Fibonacci 61.8% 0.2943
Fibonacci 50% 0.2400
Fibonacci 38.2% 0.1857
Last Price 0.1260
52-Week Low 0.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.